Derick Lau

4.8k total citations
112 papers, 3.8k citations indexed

About

Derick Lau is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Derick Lau has authored 112 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 57 papers in Pulmonary and Respiratory Medicine and 33 papers in Molecular Biology. Recurrent topics in Derick Lau's work include Lung Cancer Treatments and Mutations (44 papers), Lung Cancer Research Studies (35 papers) and Lung Cancer Diagnosis and Treatment (28 papers). Derick Lau is often cited by papers focused on Lung Cancer Treatments and Mutations (44 papers), Lung Cancer Research Studies (35 papers) and Lung Cancer Diagnosis and Treatment (28 papers). Derick Lau collaborates with scholars based in United States, Canada and India. Derick Lau's co-authors include David R. Gandara, Primo N. Lara, Allen M. Chen, John J. Crowley, D. Gregory Farwell, Kari Chansky, James A. Purdy, Kit S. Lam, Quang Luu and James R. Jett and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Clinical Cancer Research.

In The Last Decade

Derick Lau

111 papers receiving 3.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Derick Lau United States	31	1.7k	1.6k	827	607	451	112	3.8k
Kumar Prabhash India	35	2.6k 1.5×	2.5k 1.5×	816 1.0×	1.3k 2.1×	1.2k 2.6×	531	5.5k
Carlos Gil Ferreira Brazil	35	1.4k 0.8×	1.7k 1.1×	1.6k 1.9×	268 0.4×	497 1.1×	179	4.2k
Glenn Mills United States	26	930 0.5×	1.9k 1.2×	673 0.8×	178 0.3×	340 0.8×	119	3.4k
Vanita Noronha India	26	1.6k 0.9×	1.4k 0.9×	444 0.5×	792 1.3×	764 1.7×	356	3.1k
Rajendra Badwe India	33	1.1k 0.7×	3.2k 2.0×	533 0.6×	766 1.3×	1.2k 2.7×	183	5.6k
C. C. Boring United States	11	1.3k 0.8×	1.8k 1.1×	877 1.1×	173 0.3×	848 1.9×	12	4.4k
Jeffrey Tobias United Kingdom	34	1.0k 0.6×	1.6k 1.0×	416 0.5×	166 0.3×	668 1.5×	136	3.7k
Jason A. Zell United States	34	1.7k 1.0×	2.0k 1.2×	527 0.6×	155 0.3×	618 1.4×	130	3.7k
Dan J. Raz United States	34	1.4k 0.8×	1.2k 0.7×	864 1.0×	158 0.3×	464 1.0×	114	3.3k
Rajaraman Swaminathan India	30	468 0.3×	1.6k 1.0×	466 0.6×	313 0.5×	640 1.4×	96	3.4k

Countries citing papers authored by Derick Lau

Since Specialization

Citations

This map shows the geographic impact of Derick Lau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Derick Lau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Derick Lau more than expected).

Fields of papers citing papers by Derick Lau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Derick Lau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Derick Lau. The network helps show where Derick Lau may publish in the future.

Co-authorship network of co-authors of Derick Lau

This figure shows the co-authorship network connecting the top 25 collaborators of Derick Lau. A scholar is included among the top collaborators of Derick Lau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Derick Lau. Derick Lau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lau, Derick, James Moon, Angela M. Davies, et al.. (2013). Southwestern Oncology Group Phase II Trial (S0526) of Pemetrexed in Bronchioloalveolar Carcinoma Subtypes of Advanced Adenocarcinoma. Clinical Lung Cancer. 14(4). 351–355. 5 indexed citations

Chen, Allen M., et al.. (2012). Intensity-Modulated Radiotherapy is Associated With Improved Global Quality of Life Among Long-term Survivors of Head-and-Neck Cancer. International Journal of Radiation Oncology*Biology*Physics. 84(1). 170–175. 45 indexed citations

Lara, Primo N., Jeff Longmate, Karen L. Reckamp, et al.. (2011). Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non–Small-Cell Lung Cancer: A California Cancer Consortium Trial. Clinical Lung Cancer. 12(1). 33–37. 17 indexed citations

Sangha, Randeep, Angela M. Davies, Primo N. Lara, et al.. (2011). Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial. Journal of Thoracic Oncology. 6(12). 2112–2119. 25 indexed citations

Davies, Angela M., Cheryl Ho, Laurel Beckett, et al.. (2009). Intermittent Erlotinib in Combination with Pemetrexed: Phase I Schedules Designed to Achieve Pharmacodynamic Separation. Journal of Thoracic Oncology. 4(7). 862–868. 39 indexed citations

Kelly, Karen, Kari Chansky, Laurie E. Gaspar, et al.. (2008). Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023. Journal of Clinical Oncology. 26(15). 2450–2456. 421 indexed citations

Lau, Derick, et al.. (2008). Population-Based Phase I Trial of Irinotecan and Epirubicin. American Journal of Clinical Oncology. 31(3). 226–230. 1 indexed citations

Davies, Angela M., Cheryl Ho, Laurel Beckett, et al.. (2007). Phase I Study of Two Different Schedules of Bortezomib and Pemetrexed in Advanced Solid Tumors with Emphasis on Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2(12). 1112–1116. 19 indexed citations

Davies, Angela M., Raja Mudad, James Moon, et al.. (2007). PD3-1-7: Phase II trial of autologous cancer vaccine, CG8123 (GVAX), in patients with advanced bronchioloalveolar carcinoma (BAC): a Southwest Oncology Group Study (S0310).. Journal of Thoracic Oncology. 2(8). S461–S461. 5 indexed citations

10.

Wang, Henry E., Janice Ryu, David R. Gandara, et al.. (2007). A Phase II Study of Paclitaxel, Carboplatin, and Radiation with or without Surgery for Esophageal Cancer. Journal of Thoracic Oncology. 2(2). 153–157. 33 indexed citations

11.

Davies, Angela M., Cheryl Ho, Paul J. Hesketh, et al.. (2007). Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study. Investigational New Drugs. 25(4). 351–355. 5 indexed citations

12.

Lau, Derick, Linlang Guo, Ruiwu Liu, Jan Mařı́k, & Kit S. Lam. (2006). Peptide ligands targeting integrin α3β1 in non-small cell lung cancer. Lung Cancer. 52(3). 291–297. 30 indexed citations

13.

Lau, Derick, et al.. (2005). Complete response of brain metastases to irinotecan-based chemotherapy. Journal of Clinical Neuroscience. 12(3). 242–245. 4 indexed citations

14.

Lau, Derick, et al.. (2004). Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs. Critical Reviews in Oncology/Hematology. 50(2). 111–119. 20 indexed citations

15.

Lara, Primo N., Jeff Longmate, Derick Lau, et al.. (2004). Trastuzumab plus Docetaxel in HER2/neu–Positive Non–Small-Cell Lung Cancer: A California Cancer Consortium Screening and Phase II Trial. Clinical Lung Cancer. 5(4). 231–236. 83 indexed citations

16.

Hesketh, Paul J., et al.. (2002). Unfavorable Therapeutic Index of Cisplatin/Gemcitabine/Vinorelbine in Advanced non—small-Cell Lung Cancer. Clinical Lung Cancer. 4(1). 47–51. 5 indexed citations

17.

Grunberg, Steven M., John Crowley, Kenneth R. Hande, et al.. (1999). Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study. Cancer Chemotherapy and Pharmacology. 44(6). 461–468. 15 indexed citations

18.

Lara, Primo N., David R. Gandara, Gregory T. Wurz, et al.. (1998). High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically. Cancer Chemotherapy and Pharmacology. 42(6). 504–508. 8 indexed citations

19.

Gandara, David R., Martin J. Edelman, John J. Crowley, Derick Lau, & Robert B. Livingston. (1997). Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study. Cancer Chemotherapy and Pharmacology. 41(1). 75–78. 20 indexed citations

20.

Lewis, Alexander D., George E. Durán, Derick Lau, & Branimir I. Šikić. (1992). Sensitization of drug resistant human ovarian cancer cells to cyanomorpholino doxorubicin (MRA-CN) by modulation of glutathione metabolism. International Journal of Radiation Oncology*Biology*Physics. 22(4). 821–824. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact